Rawcliffe Adrian sold $67K of WVE
Rawcliffe Adrian sold 12,700 shares of Wave Life Sciences, Inc. (WVE) at $5.29 on 2026-08-12 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the director’s open-market sale details (shares, price, total value) and that it was executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note the insider sale for sentiment, but the 10b5-1 structure and lack of fundamental updates limit trading impact.
What to watch
The filing provides no context on total holdings beyond the post-transaction 0 shares, and it does not indicate whether other insiders have offsetting buys or whether any new company catalysts occurred.
Background
The article is an SEC Form 4 insider transaction disclosure for Wave Life Sciences, Inc.
Ticker impact
Wave Life Sciences disclosed a director open-market sale of 12,700 shares at $5.29 on 2026-08-12 via an SEC Form 4.
Low likelihood of a sustained price move solely from this Form 4; any impact would be sentiment-driven and likely short-lived.
The filing is a routine director sale with a pre-arranged 10b5-1 plan and no accompanying fundamental catalyst (no guidance, trial, deal, or enforcement action).
Market effects
No clear sector read-through because the disclosure is company-specific and routine insider activity.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity needs rather than a bearish view on fundamentals.
Key entities
- issuerWave Life Sciences, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderRawcliffe Adrian
Director who sold 12,700 shares at $5.2900/share under a 10b5-1 plan.
